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Over the last 25 years, asthma has emerged as
an increasingly important public health prob-
lem (Anderson et al. 1994; Rappaport and
Boodram 1998). The pathogenesis and etiol-
ogy of asthma is complex and not fully under-
stood. Although a rapid rise in childhood
asthma prevalence suggests a role for environ-
mental factors in the etiology of this evolving
epidemic, genetic susceptibility to environ-
mental stressors is also likely to inﬂuence the
occurrence of asthma (Blumenthal 2005;
Cookson 2002; Hemminki et al. 2007). 
Evidence suggests that members of the glu-
tathione S-transferase (GST) superfamily con-
tribute to asthma pathogenesis. We have
previously reported that GSTM1 is associated
with asthma risk in children exposed to tobacco
smoke (Gilliland et al. 2002b). The GST
superfamily includes a number of additional
candidate susceptibility genes for asthma
because several members, including GSTP1, are
expressed in the respiratory tract and function
in processes implicated in asthma pathogenesis,
including oxidant defenses, xenobiotic metabo-
lism, and detoxification of hydroperoxides
(Strange et al. 2001). DNA sequence variants
in the GSTP1 locus may contribute to suscepti-
bility to oxidative stress and airway inﬂamma-
tion, which are key processes in asthma
pathogenesis. A functional sequence variant in
GSTP1 at codon 105 (Ile105Val) has been
associated with asthma and susceptibility to the
adverse effects of tobacco smoke and ambient
air pollution in several studies (Aynacioglu et al.
2004; Ercan et al. 2006; Fryer et al. 2000;
Gilliland et al. 2002a, 2004; Hemmingsen
et al. 2001; Lee et al. 2004, 2005; Mapp et al.
2002; Palmer et al. 2006; Spiteri et al. 2000;
Tamer et al. 2004). Although evidence indi-
cates a role of the GSTP1 Ile105Val variant in
asthma, the effect of other common variants in
GSTP1 coding and promoter region and the
joint effects with tobacco-smoke exposure have
yet to be fully determined.
The human genome is characterized by
regions of strong linkage disequilibrium (LD)
that have been labeled as haplotype blocks by
Gabriel et al. (2002). The common genetic
variation across the region can be predicted
using only a subset of all single nucleotide
polymorphisms [haplotype tagging SNPs
(htSNPs)] (Stram et al. 2003). These can be
used to impute haplotypes and provide an
indirect assessment of potential common
causal variants that may not have been geno-
typed. To further investigate the effect of com-
mon GSTP1 variants to asthma occurrence
and susceptibility to tobacco smoke, we exam-
ined associations between common GSTP1
haplotypes, tobacco-smoke exposure, child-
hood asthma, and related symptoms among
participants in the Children’s Health Study. 
Methods
Study population. The Children’s Health
Study (CHS) recruited children from public
school classrooms from grades 4, 7, and 10 in
12 Southern California communities. At study
entry, in the spring of 1993, a parent or
guardian of each participating child completed
a self-administered questionnaire on demo-
graphics, medical and family health history,
smoking exposures, and household characteris-
tics. In the fall of 1995, a second group of
fourth-grade students was recruited and com-
pleted the same baseline questionnaire as the
group enrolled in 1993. A parent or guardian
of each participating child provided written
informed consent. Details on the design, site
selection, subject recruitment, and assessment
of health effects have previously been reported
(Gilliland et al. 2002b; Peters et al. 1999).
This analysis included 3,082 non-Hispanic
and Hispanic white children who participated
in the genetic studies. Children and a subset of
their parents (579 child–parent trios) provided
buccal cell specimens as a source of germline
DNA for genotyping. 
Outcome assessment: asthma/wheezing.
We used questionnaire responses provided by
parents or guardians to categorize children’s
asthma status, age at asthma diagnosis, and
wheezing history as previously described
(Gilliland et al. 2002b; Li et al. 2000).
Children were classified as having a lifetime
diagnosis of asthma if the adult completing
the questionnaire reported that a doctor had
ever diagnosed the child as having asthma.
Asthma onset by 3 years of age was classiﬁed
as early-onset asthma. Late-onset asthma was
defined as age of onset for asthma after
3 years of age. Current wheezing was deﬁned
as a positive response to both of the following
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BACKGROUND: Glutathione S-transferase P1 (GSTP1) plays a role in a spectrum of respiratory dis-
eases; however, the effects of sequence variation across the entire locus in asthma pathogenesis have
yet to be determined. 
OBJECTIVES: This study was designed to investigate whether sequence variations in the GSTP1 cod-
ing and promoter regions are associated with asthma and wheezing outcomes and to determine
whether variants affect susceptibility to maternal smoking.
METHODS: Four haplotype tagging SNPs were selected that accounted for 83% of the common
haplotypic variation in GSTP1. The associations of GSTP1 variants with asthma and wheezing
were assessed among white children in the Children’s Health Study (CHS).
RESULTS: The Ile105Val allele and a SNP in the upstream promoter region (SNP1: rs6591255,
putative transcription factor 1 binding site) were associated with asthma and wheezing outcomes,
an association observed in two cohorts of the CHS recruited in different years. Haplotypes that
included both the promoter SNP (i.e., rs6591255) and the 105 Val variant were associated with an
increased risk for asthma in non-Hispanic whites. Using SNP- and haplotype-based approaches, the
effect of maternal smoking on wheezing was largest in children with the Ile105Val allele. 
CONCLUSIONS: Variants in both the promoter and coding regions of the GSTP1 locus may con-
tribute to the occurrence of childhood asthma and wheezing and may increase susceptibility to
adverse effects of tobacco-smoke exposure.
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yes, has this happened in the past 12 months?”
Any medication for wheezing was assessed for
the 12 months before the interview.
Exposure assessment. Exposure assessment
methods have been previously reported
(Gilliland et al. 2002b; Peters et al. 1999). In
brief, exposure to maternal smoking during
the in utero period, secondhand-smoke expo-
sure, and the number of smokers in the
household were collected by questionnaire at
study entry. Ambient air pollutants were
monitored at central site monitors located in
each of the study communities, and average
annual exposure levels were computed.
Monitored pollutants included ozone, nitro-
gen dioxide, and particulate matter with an
aerodynamic diameter of up to 2.5 µm or
10 µm (PM2.5 and PM10). 
Genotyping. Buccal scrapes were collected
using standard protocols, and genomic DNA
was isolated using a PURGENE DNA isolation
Kit (Gentra Systems, Minneapolis, MN, USA).
The polymorphisms were identified using
allele-speciﬁc MGB probes on an ABI PRISM
7700 Sequence Detector (Applied Biosystems,
Foster City, CA, USA). The sequences of
primers and probes used are listed in the
Supplemental Material, Table 1 (online at
http://www.ehponline.org/members/
2007/10655/suppl.pdf). 
Characterizing LD and selecting htSNPs.
To investigate the LD patterns for GSTP1, we
examined resequencing data for GSTP1 in a
panel of 90 subjects provided by the National
Institute of Environmental Health Sciences
(NIEHS) Environmental Genome Project
(http://egp.gs.washington.edu/) (NIEHS
SNPs 2007) to characterize the haplotype
block structure by using Haploview version
3.3 (download from http://www.broad.mit.
edu/mpg/haploview/download.php) (Barrett
et al. 2006). One sample was not included
because only 40% of the SNPs had genotyp-
ing results. Twenty-six of the 36 SNPs found
in the sequencing were excluded because of a
lower minor allele frequency (MAF ≤ 0.20) or
a high missing rate (≥ 25%) among samples. 
As shown in Figure 1, two haplotype
blocks with substantial interblock LD were
deﬁned based on the method using the conﬁ-
dence intervals (CIs) of D´ proposed by
Gabriel et al. (2002) (with the upper CI as
0.97 and the lower CI as 0.70). The squared
correlation (Rh
2) between the true haplotypes
(h)and their estimates were calculated, and the
calculation of Rh
2 is described in detail by
Stram et al. (2003). The htSNPs were then
chosen using TagSNPs (download from http://
www-rcf.usc.edu/~stram/tagSNPs.html)
(Stram 2004). This program implements an
expectation maximization (EM) algorithm
approach to find the minimum set of SNPs
(within a block) that would have Rh
2 ≥ 0.85for
all haplotypes with an estimated frequency of
≥ 5%. We selected two htSNPs for each of the
two blocks (rs6591255 and rs4147581 for the
first block with Rh
2 = 0.87; rs1695 and
rs749174 for the second block with Rh
2 =
0.91). All four htSNPs accounted for 83% of
the haplotypic variation in the GSTP1 locus
without considering the block structure. 
Statistical analyses. SNP-based analysis.
We ﬁrst examined the association of each of
the four GSTP1 htSNPs with asthma and
wheezing outcomes using multiple logistic
Li et al.
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Table 1. Selected characteristics of non-Hispanic and Hispanic white CHS participants.a
Non-Hispanic white Hispanic white
Demographic characteristics/respiratory outcomes (n = 2,122) (n = 960)
Demographic characteristics
Percent female  51.7 56.8
Age at study entry [years (%)]
8– < 10  50.5 55.8
10– < 12  21.4 22.2
12– < 14  15.5 11.7
14–18 12.5 10.3
Gestational age (%)
Full term  87.9 91.2
< 4 weeks early  7.3 6.0
≥ 4 weeks early  4.7 2.8
With insurance (%)  88.3 73.9
Tobacco-smoke exposure (%)
In utero 19.8 10.7
Ever SHS 36.2 26.9
Current SHS 19.2 12.9
Personal smoking  1.1 0.8
Respiratory outcomes (%)
Lifetime diagnosis of asthma  15.3 13.8
Early-onset asthma  7.1 6.9
Late-onset asthma  8.2 6.9
Current wheezing  19.9 16.8
Medication for wheeze  11.4 10.2
SHS, secondhand smoke.
aParticipants with genotyping data. 
Figure 1. The location and linkage disequilibrium display of 10 resequenced GSTP1 SNPs. The data are
from the NIEHS Environmental Genome Project. The block structure of GSTP1 is deﬁned using conﬁdence
intervals of D´ among SNPs (pairwise 100 × D´ shown in the lozenge-shaped cells, an empty D´ value indi-
cates D´ = 1). Two htSNPs (circled) are selected for each block based on the Rh
2 > 0.85 criteria.
Block 1 (2 kb) Block 2 (1 kb)
GSTP1
RefSeq genesregressions. Models were adjusted for a priori
selected covariates including communities of
residence, sex, age, gestational age, and smoke
exposure (both in utero and secondhand). We
used the dominant genetic model to assess the
association of each htSNP with asthma and
wheezing outcomes. We performed a likeli-
hood ratio test (LRT) to test the global associ-
ation of four variants in GSTP1 with asthma
and wheezing outcomes. To assess confound-
ing by admixture, we examined genotype
associations in child–parent trios using a
logistic-regression model that included indica-
tors of parent mating type (Gauderman
2003). In addition, we stratified our study
population by non-Hispanic and Hispanic
whites (two major ethnic groups) to assess
whether associations differed by ethnicity. We
formally tested for ethic differences in associa-
tions, and if effect estimates and test of signif-
icance supported no ethnic differences, the
analyses were conducted in the combined
group with adjustment for ethnicity.
Haplotype-based analysis. Because phase
cannot be uniquely defined for subjects that
have heterozygous genotypes, haplotype fre-
quencies for each ethnic group (non-Hispanic
and Hispanics whites) were separately esti-
mated from the genotype data using the EM
algorithm. Following the method of Zaykin
et al. (2002) and Wallenstein et al. (1998), we
coded the haplotype as the (estimated) number
of copies of each haplotype a person carries.
For example, if one individual carries one copy
of haplotype A and one copy of haplotype B,
the coding for haplotype A and B would be
one, and the coding for the rest of the haplo-
types could be zero. The sum of all number of
copies of each haplotype for a person should be
two. Except for the most common haplotype,
which was the referent haplotype in the analy-
sis, these (estimated) numbers of copies of each
haplotype a person carries were used in a logis-
tic model with the same adjustment variables
listed above. Thus, the odds ratio (OR) for the
outcome represents the increase in risk for a
single copy of a particular haplotype relative to
the referent haplotype (Wallenstein et al.
1998). The most common haplotype was used
as the reference in the haplotype-based analysis.
Moreover, likelihood ratio tests with 5 degrees
of freedom were performed for the omnibus
test of haplotype association. All statistical
analyses were carried out by SAS version 9.1
(SAS Institute Inc., Cary, NC, USA), and
all tests were two-sided with 0.05 as the
signiﬁcant level. 
Results
The characteristics of participants in this study
are described in Table 1. Most children were
non-Hispanic white and < 10 years of age.
In utero exposure to maternal smoking
occurred among 19.8% of non-Hispanic
whites and 10.7% of Hispanic whites. Personal
smoking was rare in both ethnic groups (about
1%). Similar percentages of non-Hispanic
whites and Hispanic whites (15.3% and
13.8%, respectively) reported any lifetime
diagnosis of asthma. The prevalence of wheez-
ing in the preceding 12 months was 19.9%
and 16.8% for non-Hispanic and Hispanic
whites, respectively. About 11% of participants
took medication for wheezing. 
The genotype frequencies of the four
GSTP1 htSNPs are presented in Table 2, and
the pairwise measures (D´ and r2) of linkage
disequilibrium (LD) are shown in Table 3.
The genotype distributions of the four SNPs
were consistent with Hardy–Weinberg equi-
librium. The allele frequencies of these SNPs
differed in non-Hispanic and Hispanic
whites, and the four htSNPs appeared to
show stronger LD across the locus in non-
Hispanic whites than in Hispanic whites.
In the SNP-based analysis, the four
GSTP1 SNPs jointly explained a statistically
signiﬁcant portion of the occurrence of lifetime
asthma and wheezing occurrences (Table 4).
The overall pattern of associations was similar
in non-Hispanic and Hispanic whites,
although the association was statistically signiﬁ-
cant only in non-Hispanic whites, a finding
likely attributable to the larger sample size of
non-Hispanic whites. The variant allele of
SNP1 was associated with an increased risk for
all asthma and wheezing outcomes with no
important ethnic differences in the magnitudes
of the associations. Carrying one variant allele
of SNP2 was protective for asthma and wheez-
ing, although the association reached statistical
signiﬁcance for lifetime asthma and early-onset
asthma, again with little evidence for ethnic
differences in effects. The variant allele of
SNP3 (Ile105Val) was associated with an
increased risk of early-onset asthma. SNP4
showed a similar pattern with asthma and
wheezing as SNP1. 
Based on a priori knowledge that SNP1
and SNP3 are not in strong LD (Table 4) and
may produce functional differences in the
expression and/or enzymatic function, respec-
tively, we ﬁtted reduced models that include
only these two SNPs (Table 5). The joint
model of the two functional SNPs provided
the best ﬁt to these data and showed that carry-
ing a variant allele of SNP1 increased the risk
of asthma and wheezing, but having a variant
allele of SNP3 did not have a signiﬁcant associ-
ation with asthma and wheezing. Because the
CHS cohort actually represented two discrete
enrollment periods (a fourth-, seventh-, and
Asthma, wheezing, GSTP1, haplotypes
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Table 2. Genotype frequencies of four GSTP1 htSNPs in non-Hispanic and Hispanic white participants in
the CHS.a
Non-Hispanic white Hispanic white
GSTP1 genotype No. % No. %
SNP1 TT 741 34.9 468 48.8
(rs6591255) TA 1,024 48.3 399 41.6
AA 357 16.8 93 9.7
Minor allele (A) frequency 0.41 0.31
SNP2 CC 527 24.8 367 38.2
(rs4147581) CG 1,083 51.0 456 47.5
GG 512 24.1 137 14.3
Minor allele (G) frequency 0.50 0.38
SNP3 AA 945 44.5 279 29.1
(rs1695) AG 944 44.5 504 52.5
GG 233 11.0 177 18.4
Minor allele (G) frequency 0.33 0.45
SNP4 CC 948 44.7 539 56.2
(rs749174) CT 948 44.7 362 37.7
TT 226 10.7 59 6.2
Minor allele (T) frequency 0.33 0.25
aThe genotype distributions of the four SNPs are all in the Hardy–Weinberg equilibrium in both ethnic groups.
Table 3. Pairwise measures of linkage disequilibrium (r2a and D´b) for the GSTP1 htSNPs in non-Hispanic
and Hispanic white CHS participants.
D´ \r2 SNP1 (rs6591255) SNP2 (rs4147581) SNP3 (rs1695) SNP4 (rs749174)
Non-Hispanic white
SNP1 0.668a 0.550a 0.633a
SNP2 0.988b 0.406a 0.448a
SNP3 0.875b 0.910b 0.820a
SNP4 0.944b 0.961b 0.910b
Hispanic white
SNP1 0.269a 0.155a 0.625a
SNP2 1.000b 0.433a 0.162a
SNP3 0.534b 0.935b 0.307a
SNP4 0.906b 0.889b 0.862b
ar2: upper triangle area. bD´: lower triangle area.tenth-grade group recruited in 1993 and an
additional fourth-grade contingent in 1996),
we examined whether associations were also
observable in the two independent groups. The
results were consistent in these two groups, and
the stronger association of SNP1 compared
with SNP3 was observed in the two CHS
cohorts [Supplemental Material, Table 2
(online at http://www.ehponline.org/members/
2007/10655/suppl.pdf)].
Haplotype frequencies defined using the
four GSTP1 htSNPs are shown in Table 6. The
number and frequency of haplotypes varied
among non-Hispanic and Hispanic whites. For
example, the haplotype carrying the variant
allele for SNP3 and common alleles for the
other three SNPs (henceforth labeled h0010)
was rare in non-Hispanic whites (frequency =
0.008) and relatively common in Hispanic
whites (frequency = 0.209). With one excep-
tion, we collapsed the rare haplotypes with fre-
quency < 0.05 into a single composite category
for data analysis as indicated in Table 6 [leaving
only the haplotype that isolates the Ile105Val
variant as a separate category (h0010)]. 
Variation in the upstream region of the
locus was associated with asthma and wheez-
ing. Although the omnibus test of haplotype
association (by the likelihood ratio test with
5 degrees of freedom) was only statistically
signiﬁcant in the combined group, haplotypes
containing the variant allele of SNP1 (i.e.,
h1000 and h1011) were associated with an
increased risk of asthma (Table 7). Compared
with having two copies of the most common
haplotype (h0100), people with a copy of
h1000 were at a 1.3-fold higher risk of life-
time diagnosis of asthma (95% CI, 1.0–1.7).
Children with the haplotype h1011 showed
an increased risk for the lifetime diagnosis of
asthma compared with children carrying the
reference haplotype. In contrast, the h0010
haplotype (105Val with no other variants)
was associated with a reduced risk for current
wheezing. There were no significant ethnic
differences in these associations.
We have previously reported that variants
in GSTs affect the risk of asthma associated
with maternal smoking (Gilliland et al.
2002b). To further investigate the effect of
GSTP1 variants on the relationship between
in utero exposure to maternal smoking and
asthma/wheezing outcomes, we examined the
joint effects of the common haplotype and
in utero exposure to maternal smoking in
both ethnic groups combined because there
was little evidence for ethnic heterogeneity in
associations. Among the common haplotypes
shown in Table 6, the effects of maternal
smoking on wheezing were signiﬁcantly larger
in those with h0010 compared with the other
haplotypes (Table 8). The same pattern of
effects was observed in the h1011 haplotype
(Table 9). Because the haplotype associations
involved the GSTP1 Ile105Val SNP, we then
investigated the relationship between the
Ile105Val variant, in utero exposure to mater-
nal smoking and asthma/wheezing outcomes
(Table 10). Compared with those with no
exposure and homozygous Ile 105 genotype,
Li et al.
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Table 4. The association [OR (95% (CI)] of four GSTP1 htSNPsa with asthma and wheezing in CHS partici-
pants by single SNP models.
LRTb
Ethnicity and outcome SNP1 SNP2 SNP3 SNP4 p-Value
Non-Hispanic + Hispanic whitec
Lifetime diagnosis of asthma  1.4 (1.1–1.7) 0.8 (0.6–0.9) 1.2 (1.0–1.5)* 1.3 (1.0–1.5)* 0.022
Early-onset asthma 1.4 (1.0–1.8)* 0.7 (0.5–0.9) 1.3 (0.9–1.8) 1.4 (1.0–1.8)* 0.142
Late-onset asthma 1.4 (1.0–1.9)* 0.8 (0.6–1.0) 1.2 (0.8–1.5) 1.2 (0.9–1.6) 0.109
Current wheezing 1.3 (1.0–1.6)* 1.0 (0.7–1.1) 1.1 (0.8–1.2) 1.2 (1.0–1.4)* 0.027
Medication for wheeze 1.6 (1.2–2.0) 0.9 (0.7–1.2) 1.2 (0.9–1.5) 1.4 (1.1–1.7) 0.004
Non-Hispanic whited
Lifetime diagnosis of asthma 1.5 (1.1–1.9) 0.8 (0.6–1.0) 1.2 (0.9–1.5) 1.2 (0.9–1.5) 0.032
Early-onset asthma 1.5 (1.0–2.2)* 0.8 (0.5–1.1) 1.4 (1.0–2.0)* 1.4 (0.9–1.9) 0.209
Late-onset asthma 1.5 (1.0–2.0)* 0.8 (0.5–1.0) 1.1 (0.7–1.4) 1.1 (0.8–1.5) 0.090
Current wheezing 1.4 (1.1–1.7) 0.9 (0.7–1.2) 1.1 (0.8–1.3) 1.2 (0.9–1.4) 0.031
Medication for wheeze 1.6 (1.2–2.2) 0.9 (0.6–1.2) 1.2 (0.9–1.6) 1.3 (0.9–1.7) 0.024
Hispanic whited
Lifetime diagnosis of asthma 1.3 (0.8–1.9) 0.7 (0.4–1.0) 1.3 (0.8–2.0) 1.5 (1.0–2.1)* 0.143
Early-onset asthma 1.1 (0.6–1.8) 0.6 (0.3–1.0) 1.1 (0.6–1.9) 1.3 (0.7–2.2) 0.236
Late-onset asthma 1.4 (0.8–2.4) 0.8 (0.4–1.3) 1.5 (0.8–2.8) 1.6 (0.9–2.6) 0.469
Current wheezing 1.2 (0.8–1.7) 1.0 (0.6–1.3) 1.0 (0.7–1.5) 1.5 (1.0–2.1)* 0.108
Medication for wheeze 1.5 (0.9–2.4) 1.0 (0.6–1.5) 1.1 (0.7–1.8) 1.7 (1.0–2.6)* 0.186
aSNP1 (rs6591255): T→A; SNP2 (rs4147581): C→G; SNP3 (rs1695): A→G; and SNP4 (rs749174): C→T. bLRT: comparing the
model with the four GSTP1 htSNPs with the model without the four GSTP1 htSNPs. cModels are adjusted for communities
of residence, sex, age, gestational age, smoke exposure, and Hispanic ethnicity. dModels are adjusted for communities of
residence, sex, age, gestational age, and smoke exposure.
*p < 0.05 although the conﬁdence upper/lower limit is 1.0.
Table 5. Multiple logistic-regression models [OR (95% CI)] considering two potential functional GSTP1
SNPs.a
LRTb
Ethnicity and outcome SNP1 SNP3 p-Value
Non-Hispanic + Hispanic whitec
Lifetime diagnosis of asthma 1.4 (1.0–1.8)* 1.0 (0.7–1.3) 0.008
Early-onset asthma 1.2 (0.8–1.7) 1.2 (0.8–1.7) 0.090
Late-onset asthma 1.5 (1.0–2.1)* 0.9 (0.6–1.2) 0.033
Current wheezing 1.5 (1.1–1.8) 0.9 (0.6–1.0) 0.009
Medication for wheeze 1.7 (1.2–2.3) 0.9 (0.6–1.1) 0.001
Non-Hispanic whited
Lifetime diagnosis of asthma 1.6 (1.1–2.3) 0.9 (0.6–1.2) 0.009
Early-onset asthma 1.3 (0.7–2.2) 1.2 (0.7–1.9) 0.067
Late-onset asthma 1.8 (1.1–2.9) 0.7 (0.4–1.1) 0.030
Current wheezing 1.7 (1.2–2.3) 0.8 (0.5–1.0) 0.005
Medication for wheeze 1.9 (1.2–2.8) 0.8 (0.5–1.2) 0.004
Hispanic whited
Lifetime diagnosis of asthma 1.2 (0.8–1.8) 1.2 (0.7–1.9) 0.277
Early-onset asthma 1.1 (0.6–1.9) 1.1 (0.5–1.9) 0.886
Late-onset asthma 1.3 (0.7–2.2) 1.4 (0.7–2.6) 0.233
Current wheezing 1.2 (0.8–1.7) 1.0 (0.6–1.4) 0.622
Medication for wheeze 1.6 (0.9–2.5) 1.0 (0.5–1.6) 0.162
aSNP1 (rs6591255): T→A; SNP3 (rs1695): A→G. bLRT: comparing the model with the two GSTP1 SNPs with the model with-
out the GSTP1 SNPs. cModels are adjusted for communities of residence, sex, age, gestational age, smoke exposure, and
Hispanic ethnicity. dModels are adjusted for communities of residence, sex, age, gestational age, and smoke exposure.
*p < 0.05 although the conﬁdence upper/lower limit is 1.0.
Table 6. Haplotype frequencies of four GSTP1
htSNPs in non-Hispanic and Hispanic white partici-
pants in the CHS.
Non-Hispanic white Hispanic white
Haplotypea Frequency Haplotypea Frequency
0100 0.4804 0100 0.3687
1011 0.3012 1011 0.2188
1000 0.0832 0010 0.2087
0000 0.0832 0000 0.0990
0010 0.0078 1000 0.0670
1001b 0.0173b 1001b 0.0148b
0110b 0.0083b 0111b 0.0081b
1010b 0.0055b 0011b 0.0046b
0111b 0.0055b 1010b 0.0041b
0011b 0.0033b 0001b 0.0029b
0001b 0.0021b 0110b 0.0026b
1100b 0.0010b 0101b 0.0008b
1110b 0.0008b
1101b 0.0005b
a1: minor allele and 0: common allele, by the order of SNP1
(rs6591255): T→A; SNP2 (rs4147581): C→G; SNP3 (rs1695):
A→G; and SNP4 (rs749174): C→T. bHaplotypes were col-
lapsed into a single composite category in the haplotype
analyses.children exposed to in utero maternal smok-
ing and carrying at least one variant GSTP1
Ile105Val allele had about twice the risk of
current wheezing and requiring medication
for wheeze (OR = 1.9 for both; and 95% CI,
1.3–2.6 and 1.2–2.8, respectively; interaction
p-value = 0.04 for both). Consistent with an
important role of the Val105 variant in the
association between in utero exposure to
maternal smoking and asthma/wheezing,
h1011 modified the effect of in utero expo-
sure to maternal smoking (Table 9); however,
SNP1 and SNP4 did not modify the associa-
tion in the SNP-based analyses. 
To assess the potential for confounding by
admixture, we investigated the genetic associa-
tions in a cohort subsample of 579 child–par-
ent trios (for both diseased and nondiseased
children). The trio analysis showed that the
risk estimates were generally consistent with
the results for the entire cohort. The point
estimates for SNP1 and SNP4 were higher
[Supplemental Material, Table 3 (online at
http://www.ehponline.org/members/
2007/10655/suppl.pdf)], but the conﬁdence-
intervals width was about twice as wide in the
trio analysis as in the main study, reflecting
the smaller sample size of complete trios. 
The effect of GSTP1 on asthma and
wheezing did not differ with respect to sex,
secondhand-smoke exposure, number of
smokers in the household, personal smoking,
and ambient air pollutants including ozone,
nitrogen dioxide, and PM2.5 and PM10 (data
not shown). 
Discussion
We found that DNA sequence variants in
both the promoter and coding regions of the
GSTP1 locus may contribute to the occur-
rence of childhood asthma and wheezing. The
overall evidence is consistent with a complex
age-dependent role in the pathogenesis of
asthma and wheezing for the GSTP1
Ile105Val SNP, which affects enzyme func-
tion. Furthermore, the effect of in utero expo-
sure to maternal smoking on current
wheezing and medication for wheeze depends
primarily on the GSTP1 105Val variant allele
both in the haplotype (h0010) and SNP
analyses. Our ﬁnding that a potentially func-
tional SNP located in the promoter region of
GSTP1 is associated with asthma is novel and
suggests that transcriptional regulation may
be important in asthma development. 
GSTP1 is located on chromosome 11q13,
a previously suggested candidate region for
asthma, bronchial hyperresponsiveness, and
asthma-associated quantitative traits in some
linkage studies (Doull et al. 1996). The mech-
anism for the effects of GSTP1 on respiratory
illnesses may involve pathways that affect
responses to oxidative stress (Ercan et al. 2006;
Hayes and Strange 2000). GSTs contribute to
protection against oxidative stress by using
glutathione to detoxify a variety of elec-
trophilic compounds including oxidized lipid,
DNA, and catechol products generated by
reactive oxygen species–induced damage to
intracellular molecules (Hayes and Strange
1995, 2000). Because GSTP1 is strongly
expressed in the respiratory epithelium and is
Asthma, wheezing, GSTP1, haplotypes
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Table 7. The association [OR (95% CI)] of common GSTP1 haplotypes with asthma and wheezing in CHS
participants.
Lifetime diagnosis Early-onset Current Medication 
Ethnicity and haplotype of asthma  asthma wheezing  for wheeze
All whitea
h0100b 1.0 1.0 1.0 1.0
h0000b 1.1 (0.8–1.4) 1.1 (0.7–1.6) 1.1 (0.8–1.4) 1.0 (0.7–1.4)
h0010b 0.9 (0.7–1.3) 1.2 (0.8–1.8) 0.7 (0.5–0.9) 0.7 (0.5–1.0)
h1000b 1.3 (1.0–1.7) 1.2 (0.8–1.8) 1.1 (0.9–1.4) 1.3 (0.9–1.8)
h1011b 1.2 (1.0–1.5) 1.3 (1.0–1.7) 1.1 (0.9–1.3) 1.2 (1.0–1.4)
Others 1.0 (0.7–1.6) 1.3 (0.8–2.2) 1.0 (0.7–1.5) 1.0 (0.6–1.6)
p-Value of LRTc 0.059 0.253 0.055 0.045
Non-Hispanic whited
h0100b 1.0 1.0 1.0 1.0
h0000b 0.9 (0.7–1.3) 0.8 (0.4–1.4) 1.1 (0.8–1.5) 1.0 (0.7–1.5)
h0010b 0.7 (0.2–2.3) 1.8 (0.5–5.9) 0.7 (0.3–2.0) 0.5 (0.1–2.4)
h1000b 1.4 (1.1–2.0) 1.2 (0.8–1.9) 1.2 (0.9–1.6) 1.4 (0.9–2.0)
h1011b 1.2 (1.0–1.5) 1.3 (0.9–1.7) 1.1 (0.9–1.4) 1.2 (0.9–1.5)
Others 0.9 (0.6–1.5) 1.2 (0.6–2.1) 0.9 (0.6–1.4) 0.9 (0.5–1.5)
p-Value of LRTc 0.058 0.296 0.408 0.215
Hispanic whited
h0100b 1.0 1.0 1.0 1.0
h0000b 1.4 (0.9–2.2) 1.6 (0.9–3.1) 1.0 (0.6–1.5) 0.9 (0.5–1.6)
h0010b 1.1 (0.7–1.6) 1.3 (0.7–2.2) 0.8 (0.5–1.1) 0.8 (0.5–1.3)
h1000b 1.0 (0.5–1.8) 1.2 (0.5–2.6) 0.9 (0.6–1.6) 1.2 (0.7–2.2)
h1011b 1.4 (1.0–2.1) 1.4 (0.8–2.4) 1.1 (0.8–1.6) 1.2 (0.8–1.9)
Others 1.6 (0.8–3.3) 2.0 (0.8–5.1) 1.4 (0.7–2.8) 1.4 (0.6–3.2)
p-Value of LRTc 0.257 0.407 0.460 0.501
aModels are adjusted for communities of residence, sex, age, gestational age, smoke exposure, and Hispanic ethnicity.
b1: minor allele and 0: common allele, by the order of SNP1 (rs6591255): T→A; SNP2 (rs4147581): C→G; SNP3 (rs1695):
A→G; and SNP4 (rs749174): C→T. cLRT (likelihood ratio test): the omnibus test of haplotype association. dModels are
adjusted for communities of residence, sex, age, gestational age, and smoke exposure.
Table 8. Joint effect of in utero exposure [OR (95% CI)] to maternal smoking and GSTP1 haplotype h0010
with asthma and wheezing outcomes, non-Hispanic and Hispanic whites combined.a
In utero exposure to maternal smoking 
Outcome h0010 No Yes
Lifetime diagnosis of asthma No 1.0 1.1 (0.7–1.6)
Yes 1.2 (0.9–1.5) 1.4 (0.9–2.0)
Early-onset asthma No 1.0 1.7 (0.9–2.9)
Yes 1.4 (0.9–1.9) 2.0 (1.1–3.3)
Late-onset asthma No 1.0 0.7 (0.3–1.3)
Yes 1.1 (0.8–1.5) 1.0 (0.6–1.7)
Current wheezingb No 1.0 1.2 (0.7–1.7)
Yes 0.9 (0.7–1.1) 1.9 (1.3–2.6)
Medication for wheezeb No 1.0 0.9 (0.5–1.5)
Yes 1.1 (0.8–1.3) 1.9 (1.2–2.8)
aModels are adjusted for ethnicity, communities of residence, sex, age, gestational age, and secondhand-smoke exposure.
bSigniﬁcant interaction between in utero exposure to maternal smoking and GSTP1 haplotype h0010.
Table 9. Joint effect of in utero exposure [OR (95% CI)] to maternal smoking and GSTP1 haplotype h1011
with asthma and wheezing outcomes, non-Hispanic and Hispanic whites combined.a
In utero exposure to maternal smoking 
Outcome h1011 No Yes
Lifetime diagnosis of asthma No 1.0 1.2 (0.8–1.7)
Yes 1.3 (1.0–1.6) 1.5 (0.9–2.1)
Early-onset asthma No 1.0 1.7 (1.0–2.8)
Yes 1.4 (1.0–1.9) 1.9 (1.0–3.1)
Late-onset asthma No 1.0 0.8 (0.4–1.4)
Yes 1.3 (0.9–1.7) 1.2 (0.6–1.9)
Current wheezing  No 1.0 1.4 (0.9–2.0)
Yes 1.1 (0.9–1.3) 2.1 (1.4–3.0)
Medication for wheeze  No 1.0 1.3 (0.8–2.1)
Yes 1.4 (1.0–1.7) 2.0 (1.2–3.1)
aModels are adjusted for ethnicity, communities of residence, sex, age, gestational age, and secondhand-smoke exposure.the dominant GST in the lung, variation in
GSTP1 function may have larger effects on
respiratory health outcomes than do other
members of the GST superfamily. The role of
GSTP1 protecting against reactive oxygen
species and their secondary products may be
mediated by the 105 variant (Peterhans 1997). 
To our knowledge, the association
between SNP1 (rs6591255) with asthma and
wheezing has not been previously reported.
Based on the SNP- and haplotype-based
analyses in the present study, such association
of SNP1 is not attributable to the LD with the
GSTP1 Ile105Val allele. This SNP is located
in a putative transcription factor 1 (TCF-1)
binding site upstream of the transcription start
site and may potentially be a functional SNP.
However, the role of TCF-1 in asthma patho-
genesis has yet to be determined. The pro-
moter region is complex and could harbor
other functional variants in LD with SNP1.
Cauchi et al. (2006) completely sequenced the
promoter region of the GSTP1 gene in 40
Euro-Caucasian individuals and reported that
one common haplotype comprising the com-
mon allele of the SNP1 in the present study
interacts with chemopreventive exposure in
luciferase reporter constructs. This novel ﬁnd-
ing is consistent with our ﬁnding that SNP1 is
an upstream SNP important in reducing the
risk of asthma and wheezing symptoms. The
role of the promoter region of GSTP1 needs
further study to verify whether the association
reported here is attributable to LD with
another functional SNP or its own functional-
ity as a TCF-1 binding site. 
Our study has some potential limitations
that may influence the interpretation of our
results. We recognize that asthma is a com-
plex disease, and studying only the GSTP1
gene does not provide a complete picture of
genetic susceptibility. Interaction between
GSTP1 and GSTM1 has been reported for
xenobiotic enhancement of allergic responses
(Gilliland et al. 2004) and on childhood
asthma risk (Lee et al. 2005). In the present
study, there is insufficient power to assess
higher-order interactions between GSTP1
SNPs and haplotypes with other genes and
smoking.
Selection bias is a common concern in
cross-sectional studies. The group of children
with genotyping data included in this analysis
did not differ substantially from those without
genotyping data on a broad range of demo-
graphic, medical history, and household expo-
sure factors [Supplemental Material, Table 4
(online at http://www.ehponline.org/mem-
bers/2007/10655/suppl.pdf)]. Therefore, selec-
tion bias is an unlikely explanation for our
ﬁndings. Another possible limitation might be
recall bias with regard to early life events. To
evaluate this possibility, we resurveyed
691 study participants about the mother’s
smoking history during pregnancy and about
asthma status in a counter-matched case–con-
trol study nested in the CHS (Li et al. 2005) as
we tried to investigate the dose effect of smok-
ing. The kappa coefﬁcients for the agreement
between the two repeated measurements were
0.80 and 0.75 for asthma and smoking, respec-
tively. The agreement is acceptable, especially
as the agreement of smoking was not statisti-
cally significantly different by asthma status.
We assessed recall of asthma status in the same
nested case–control study and found that the
concordance of parental reports of asthma and
medical records’ documentation of asthma was
good. Based on the 2001 National Health
Interview Survey, it was estimated that 113.4
per 1,000 Americans had been diagnosed with
asthma by a physician in their lifetime, and,
among children 5–17 years of age, the lifetime
prevalence was 144.2 per 1,000 which was
close to the prevalence of asthma in the present
study (American Lung Association 2006).
Moreover, we observed the same results when
we excluded early transient wheezing cases
[Supplemental Material, Table 5 (online at
http://www.ehponline.org/members/2007/
10655/suppl.pdf)]. Population stratification
can be a concern in genetic association studies.
In our investigation, although the estimates
were more uncertain because of a smaller sam-
ple size in the trio analyses, the case–control
and complete trio analyses indicate that con-
founding by population substructure is
unlikely to explain our ﬁndings. 
Some of our results were based on a hap-
lotype approach. The selection of htSNPs was
based on 90 individual genotypes provided by
the NIEHS Environmental Genome Project.
Although haplotype analysis is very depen-
dent on the deﬁnition of blocks, it was not an
issue for the present study because the four
SNPs selected for this study represented >
80% of the general population’s variation.
The EPG data did not carry ethnicity identi-
fiers, so we could not stratify the data when
selecting htSNPs. However, we assessed how
well the four selected htSNPs represented the
haplotype diversities in two other ethnically
identiﬁed subgroups, each containing 70 indi-
viduals. The Rh
2 was 0.76 and 0.71 respec-
tively for non-Hispanic and Hispanic whites,
implying that the four selected htSNPs had
good coverage for the two ethnic groups in
the present study. Nevertheless, the ability to
detect a true disease variant using a haplotype
approach can be attenuated if the variant is
distributed across several haplotypes in the
population and the Ile105Val allele is split
into two major haplotypes in Hispanic
whites. In our analyses, we adopted the com-
monly used approach of clustering rare haplo-
types into a composite category. However,
this composite category likely included one or
more haplotypes carrying the disease variant,
thereby reducing the analytical power to con-
trast this variant against other haplotypes.
In summary, the GSTP1 locus is associ-
ated with asthma and wheezing outcomes in
children. Both the well-studied Ile105Val
variant and an upstream SNP are associated
with the risk of asthma; however, the effects
appear to occur in opposite directions. This
pattern may explain some of the inconsisten-
cies in previous studies of the 105 variant and
asthma. The 105Val allele variant appears to
modulate the effects of in utero exposure to
maternal smoking on asthma and wheezing.
Additional studies of sufﬁcient size are needed
to independently replicate and expand our
findings to investigate sequence variation in
the promoter region of the GSTP1 gene and
the interaction of GSTP1 haplotypes with
other genes and environmental/endogenous
sources of reactive oxygen species. 
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